Drug 1
Generic/Working Name	Crizotinib
Trade Name	Xalkori
Company Name	Pfizer Inc.
Drug Type	Small molecule
Drug Class	ALK inhibitor
Dose	250 milligrams (mg) per flat dose
Route	Oral (p.o.)
Schedule of Administration	Dose level –1: 250 mg b.i.d. as monotherapy for 3 weeks (lead‐in) then in combination with pembrolizumab
Drug 2
Generic/Working Name	Pembrolizumab
Trade Name	Keytruda
Company Name	Merck Sharp & Dohme
Drug Type	Monoclonal antibody
Drug Class	Programmed death receptor‐1 (PD‐1 blocking antibody)
Dose	200 milligrams (mg) per flat dose
Route	IV
Schedule of Administration	Dose level –1: 200 mg every 3 weeks after crizotinib monotherapy lead‐in period
Abbreviations: ALK, anaplastic lymphoma kinase; b.i.d., twice a day; p.o., by mouth.